. Primer pairs used for sequence and restriction enzyme analysis of human GLUT9 gene 5'-AGAAAATAGATTAAGTCCTTCCACTG-3' 5'-TGAACATTCCCACTGTGCTG-3'
Exon 10 5'-GGTGACCATATCCATCCAG-3' 5'-GAAGGAGCACCTTAAGGTTG-3'
R380W
(cgg→tgg) 00BtsCI
Exon 11 5'-ACCCATCAACCCATCATC-3' 5'-CCTTCTGTGGGATAGACTGC-3' ) Exon 12 5'-GTGTGGCAGATGGAGATGG-3' 5'-AGTGCTGCAGAATCAAAGGG-3'
Exon 13-1 (coding) 5'-TTGAGCCAGCATCACACATGG-3' 5'-TCCTTGCAGCTTCCAGAAGGG-3'
Exon 13-2 (3'UTR)
Primers for the analysis of GLUT9 exon 10 were designed so that PCR amplification and the following BtsCI digestion result in one band (757 bp) from the normal controls, but an additional two bands (408 bp and 349 bp) from the R380W mutant samples. Primers for analysis of GLUT9 exon 6 were designed based on a similar concept, so that PCR amplification followed by AlwI digestion results in two distinct bands (378 bp and 259 bp) from the normal controls, but in one band (637 bp) from the R198C mutant samples.
Figure S1. Subcellular localization of wild-type or mutated GLUT9 in oocytes.
Immunodetection with anti-GLUT9 shows that GLUT9L proteins (wild type, R380W, and R198C) are expressed on the plasma membrane (arrowheads), whereas fluorescence remains undetectable in water-injected control oocytes. Bar = 50 μm. 
Takifugu rubripes
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Figure S2. Amino acid conservation in GLUT9 vertebrate orthologs.
Arginine residues orthologous to human GLUT9 amino acid positions 380 and 198, which are the sites of missense mutations identified in hypouricemia patients, are boxed in magenta.
Page 2 of 5 Control R380W Wild type R198C Figure S3 . Conserved arginine residues in sugar transport proteins signatures 1/2. Pathogenic mutation sites (magenta) of GLUT9 (R380 and R198) and GLUT1 (R333 and R153) in consensus patterns 1/2 (blue) are highly conserved among the sugar transport proteins of yeast, bacteria, plants, and mammals. In the sugar transport proteins signatures 1 or 2, each residue (magenta) of the pathogenic mutation sites is found to be the most highly conserved arginine residue, which may be the determinant of membrane topology. Alignment data are retrieved from PROSITE (also see Web Resources and Accession Numbers in the main text), which shows perfect amino acid conservation in 374 or 350 sequences of transporters for sugar transport proteins signatures 1 and 2. Representative data of transport proteins from Saccharomyces cerevisiae, Escherichia coli, Arabidopsis thaliana, and Homo sapiens are shown in this figure.
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Homo sapiens Pathogenic mutation sites for GLUT9 and GLUT1 Figure S4 . The effects of co-expression of wild-type and mutant GLUT9 on urate transport activities.
Oocytes were injected with 12.5 ng of wild-type GLUT9L cRNA or mutant cRNA (R380W, R198C). For co-expression studies, both wild-type GLUT9L cRNA (12.5 ng) and mutant cRNA (12.5 ng) were co-injected to test the possibilities of dominant negative effects. Urate transport activities in oocytes injected with mutant cRNA (R380W, R198C) were markedly reduced, but those in co-injected oocytes (wild type + R380W, wild type + R198C) were not reduced. Results are expressed as mean ± SEM. Figure S5 . The P412R mutation is unlikely to be a pathogenic mutation for renal hypouricemia.
P412R
(A,B) The results of oocyte expression studies are displayed. Neither the P412R mutation in GLUT9L nor the P383R mutation in GLUT9S, which correspond to P412R in GLUT9L, reduced their urate transport activities at all. In contrast, pathogenic mutants of GLUT9L (R380W and R198C) and GLUT9S (R351W and R169C) markedly reduced their urate transport (4.6-10.8%). The extent of the reduction in urate transport from GLUT9 pathogenic mutations in our functional analyses are quite similar to those from URAT1 pathogenic mutations for renal hypouricemia. Also, the results from the GLUT9L mutants (A) are quite similar to those from the GLUT9S mutants (B), suggesting the reproducibility and reliability of the results. The reproducibility of the results was confirmed by three independent experiments using different batches of oocytes and in vitro transcribed cRNA. These data prove that P412R in GLUT9L and P383R in GLUT9S do not reduce the urate transport activities. Even if the P412R GLUT9 mutant showed moderate reduction in the urate transport activity as recently reported (about 60%) (Anzai, et al., J. Biol. Chem. 2008) , the extent of functional reduction is not sufficient to cause clinical hypouricemia. These findings suggest that P412R is unlikely to be a pathogenic mutation for renal hypouricemia. Results are expressed as mean ± SEM. (C) The site of P412R is not conserved in the GLUT family transporters. In contrast, the pathogenic mutation sites R380W and R198C, which we identified in this study, are highly conserved in GLUT family transporters.
The extent of the reduction in urate transport (%) is calculated as follows; [(Uptake by mutant GLUT9-expressed oocytes) -(Uptake by control oocytes)] / [(Uptake by wild-type GLUT9-expressed oocytes) -(Uptake by control oocytes)] ×100.
